Some consumers take tiny doses of Ozempic and other GLP-1 drugs or stretch out doses to cut costs and side effects.

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

(Reuters) -After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs ...

The U.S. Environmental Protection Agency has drafted a plan to eliminate all limits on greenhouse gases from coal and ...

By Sriparna Roy (Reuters) -After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective ...

Your commitment strengthens our ability to report fearlessly on the topics that matter most to you.

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending flexibilities for compounded products. The grace period for manufacturers to ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), GE Aerospace ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

(Lovelace Jr., 12/19) AP: FDA Says Knockoff Versions Of Lilly Obesity Drug Must Come Off The Market Specialty ... The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s ...